ADGM

Adagio Medical Holdings, Inc. (ADGM) Economic Moat Analysis (2026)

Invetso Score: 0.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.0 (Weak)

ADGM shows no evidence of durable brand, patent, regulatory, or data advantages in the provided filings-based inputs, so it lacks the kind of protected asset base that would support pricing power versus peers.

The absence of positive profitability and the negative ROIC/ROCE imply any intangible edge is not translating into economic returns, unlike stronger peers where protected assets typically sustain margins.

No disclosed customer, product, or IP lock-in is provided, which means intangible assets appear replicable rather than defensible over a 5–10 year horizon.

Switching Costs

Score:

The provided metrics do not indicate recurring contracts, embedded workflows, or integration depth, so customers appear able to switch without meaningful economic friction.

Extremely weak cash conversion cycle and zero asset turnover suggest the business is not demonstrating the kind of retained usage or renewal behavior that usually signals switching costs.

Compared with peers that benefit from mission-critical software, regulated infrastructure, or long-term service entrenchment, ADGM shows no visible evidence of retention-based moat.

Network Effects

0

There is no evidence of user, data, or ecosystem feedback loops in the supplied information, so the business does not appear to gain value as adoption rises.

Negative returns and no observable scale efficiency argue against a self-reinforcing platform dynamic, unlike peers with clear two-sided or data network effects.

Without disclosed participation density or ecosystem dependence, network effects cannot be supported as a moat driver.

Cost Advantage

Score:

The negative ROIC and ROCE indicate the company is not converting operations into a cost position superior to peers.

A cash conversion cycle above 5,000 days is inconsistent with a structurally efficient operating model, so there is no evidence of durable unit-cost advantage.

Relative to peers with procurement scale, process automation, or asset-light economics, ADGM does not show a visible cost moat in the provided data.

Efficient Scale

Score:

The available information does not show that ADGM operates in a niche where one or two firms can serve the market at lower cost than multiple rivals.

Negative capital returns suggest scale is not yet producing the fixed-cost absorption or market-share stability needed for efficient-scale protection.

Compared with peers in concentrated markets, ADGM does not present evidence of capacity discipline, regulatory scarcity, or natural monopoly characteristics.

Overall Score

Score:

ADGM shows no observable structural moat in the provided data, because none of the five moat drivers is supported by evidence of durable pricing power, retention, or superior economics versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Adagio Medical Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →